NextCure
Biotechnology · 43 employees
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies to treat cancer. They aim to bring first-in-class and best-in-class treatments to market. Their research is centered around innovative antibody-drug conjugates and other biologics.
Funding history
- Venture - Series Unknown — $21.5M — Dec 2025
- Post-IPO Equity — $10.0M — Nov 2025
- Venture - Series Unknown — $93.4M — Nov 2018
- Venture - Series Unknown — $15.0M — Jan 2016
Recent signals
- Jul 14, 2026: NextCure to merge with Avere Therapeutics for IL-23 therapy
- Dec 10, 2025: Raised $21.5M in Venture - Series Unknown
- Nov 17, 2025: Raised $10.0M in Post-IPO Equity
- Nov 12, 2025: SEC 8-K (1.01): On November 12, 2025, NextCure, Inc. entered into a securities purchase agreement with institutional and accredited investors for a private placement. The agreement includes the sale of 708,428 shares of common stock at a price of $8.52 per share and pre-funded warrants for the purchase of up to 1,815,049 shares at a price of $8.519 per warrant. This private offering aims to raise capital for the company, and has implications for NextCure's financing strategy in the competitive biotech market.
- Jun 16, 2025: NextCure and Simcere Zaiming Form Strategic Partnership for SIM0505, an Antibody-Drug Conjugate Targeting CDH6.
- Nov 19, 2018: Raised $93.4M in Venture - Series Unknown
- Jan 11, 2016: Raised $15.0M in Venture - Series Unknown
See plans & pricing → Track NextCure’s funding, hiring, and signals — with verified contacts — on Fundz.